All Posts Tagged With: "biofilm"

Full article: http://betterhealthguy.com/joomla/blog/216-ilads-2010-conference-takeaways

Excerpt:

In October 2010, I attended the ILADS 2010 Annual event.  The event was packed.  Almost 400 people attended in person and over 1,000 people watched on the live webcast.  It is exciting to see so many people taking an interest in this controversial area of medicine.  The event was full of great information and people working hard to help us all find answers.

In this blog entry, I will share a few of the key takeaways that I learned at the event.  The slides from the event are available for purchase here for a very reasonable $40.  The DVDs (Friday’s sessions) and CDs of the presentations can be obtained from ZenWorks Productions.  Thus, I am not going to attempt to repeat information that is available elsewhere, but I will focus on some of the key things that caught my attention.

• The 2011 ILADS event will be in Toronto, Canada – October 28-30, 2011

• Dr. Richard Horowitz proposed that Chronic Lyme is really MCIDS – MultipleChronic Infectious Disease Syndrome

• Biofilm treatment may be with EDTA or a Banderol/Samento combination.  There may be a strong antigen release with biofilm treatment which may make it a good candidate for pulsed therapy

• Dr. Steve Harris mentioned that yeast may cannibalize dying Borrelia and that yeast is not always the result of antibiotic therapy alone.  He suggested up to 100 billion probiotic organisms daily.  In terms of diet, he said, “If it’s white, it ain’t right”

• Minocycline may have longer toxic effects than doxycycline but has better CNS penetration.  Mino also has less sun sensitivity than doxy.  That said, Dr. Joe Burrascano commented that the effectiveness of minocycline may be regional as he never observed it working well in his patients

Linda’s comment:  Zeo Gold ROCKS….I have been taking Zeo Gold fromwww.longevityplus.com since it came out….I started with the ACZnano Zeolite, which binds in the body so it doesn’t bounce back, then I graduated to the Zeo Gold, but still take 5 sprays 4-5 times daily of the ACZnano Zeolite….This product is everything that Dr Gordon says it is….I won’t be without it…Both of these are part of the FIGHT protocol and I have been dissolving biofilms using the FIGHT  protocol….

Zeo Gold works on everyone due to the SYNERGY of its world class ingredients. There are extensive research papers on each ingredient that stand alone as proven effective so taken all together you may feel years younger in a few weeks.

YOU will want to work to higher doses slowly to increase the effects you feel; toxins took years to accumulate and this just gets better and better. You will be getting rid of toxins and the fecal changes alone will amaze you at higher doses, as the Biofilm is changed. 

How is ZEO GOLD changing lives? It has set a new standard for effective lifetime detoxification that you feel, and can see, and document increased exercise tolerance, memory, aches and pains gone. There is nothing that does not improve from sexual energy to sleep patterns, as you really lower all toxins in your body, not just lead. 

The synergy from the five proven ingredients is just part of the story; each ingredient is also the best in its class! The exciting feedback from users of Zeo Gold tells us that this product is a home run. 

The active ingredients in Zeo Gold include the most advanced form of Lipoic acid available anywhere. Zeo Gold contains an advanced form of Lipoic acid shown to absorb 21 times better. When you understand the proven benefits of Lipoic acid you will not go a day without taking the best. I am sure that you are not getting this form of Lipoic acid now.  This form changes everything.  (Alpha Free, Synthetic Free). 

The University of Pennsylvania has proven that some forms of oral Glutathione are effective, not a waste as many continue to mistakenly believe. 

The Humic Acid in ZeoGold is premium Grade which has been the subject of extensive scientific research and has been shown to aid the body’s ability to maintain overall health. The Zeolite sets new standards for efficacy, as it provides at least 10 times the surface area of any other zeolite for human consumption available anywhere. 

The Ascorbic Acid is the world‘s leading Vitamin C product, BioEn’R-G’y C with METHYLATION factors (MSM, TMG) and more.

If you are not treating yourself and your family with this product, you are wasting valuable time as it takes time to increase the dose since there are real changes in your stool frequency for the first two plus months as toxins leave.

Garry F. Gordon MD,DO,MD(H)
President, Gordon Research Institute
www.gordonresearch.com

Excerpt:

Research Abstract
BACKGROUND: The racemic mixture, RS-(+/-)-alpha-lipoic acid (rac-LA) has been utilized clinically and in a variety of disease models. Rac-LA and the natural form, R-lipoic acid (RLA), are widely available as nutritional supplements, marketed as antioxidants. Rac-LA sodium salt (NaLA) or rac-LA potassium salt (KLA) has been used to improve the aqueous solubility of LA. 

STUDY RATIONALE: Several in vitro and animal models of aging and age-related diseases have demonstrated efficacy for the oral solutions of LA salts in normalizing age-related changes to those of young animals. Other models and studies have demonstrated the superiority of RLA, the naturally occurring isomer over rac-LA. Despite this, RLA pharmacokinetics (PK) is not fully characterized in humans, and it is unknown whether the concentrations utilized in animal models can be achieved in vivo. Due to its tendency to polymerize, RLA is relatively unstable and suffers poor aqueous solubility, leading to poor absorption and low bioavailability. A preliminary study demonstrated the stability and bioavailability were improved by converting RLA to its sodium salt (NaRLA) and pre-dissolving it in water. The current study extends earlier findings from this laboratory and presents PK data for the 600-mg oral dosing of 12 healthy adult subjects given NaRLA. In addition, the effect of three consecutive doses was tested on a single subject relative to a one-time dosing in the same subject to determine whether plasma maximum concentration (Cmax) and the area under the plasma concentration versus time curve (AUC) values were comparable to those in animal studies and those achievable via intravenous infusions in humans. 

METHODS: Plasma RLA was separated from protein by a modification of a published method. Standard curves were generated from spiking known concentrations of RLA dissolved in ethanol and diluted in a phosphate-buffered saline (PBS) into each individual’s baseline plasma to account for inter-individual differences in protein binding and to prevent denaturing of plasma proteins. Plasma RLA content was determined by the percent recovery using high-performance liquid chromatography (electrochemical/coulometric detection) (HPLC/ECD). 

RESULTS: As anticipated from the preliminary study, NaRLA is less prone to polymerization, completely soluble in water, and displays significantly higher Cmax and AUC values and decreased time to maximum concentration (Tmax) and T1/2 values than RLA or rac-LA. In order to significantly extend Cmax and AUC, it is possible to administer three 600-mg RLA doses (as NaRLA) at 15-minute intervals to achieve plasma concentrations similar to those from a slow (20-minute) infusion of LA. This is the first study to report negligible unbound RLA even at the highest achievable plasma concentrations.
(Altern Med Rev 2007;12(4):343-351)

Excerpt:

We previously identified ebpR, encoding a potential member of the AtxA/Mga transcriptional regulator family, and showed that it is important for transcriptional activation of the Enterococcus faecalis endocarditis and biofilm associated pilus operon, ebpABC. Although ebpR is not absolutely essential for ebpABC expression (100-fold reduction), its deletion led to phenotypes similar to those of an ebpABC mutant such as absence of pili at the cell surface and, consequently, reduced biofilm formation. A non-piliated ebpABC mutant has been shown to be attenuated in a rat model of endocarditis and in a murine urinary tract infection model, indicating an important participation of the ebpRABC locus in virulence. However, there is no report relating to the environmental conditions that affect expression of the ebpRABC locus.